The main goals of the study are to describe how crizanlizumab (SEG101) works, how it moves through the body, and to measure its safety and effectiveness.
Participants in the study must be adult sickle cell disease patients with vaso-occlusive crises.
Here is some information that may help you gain a better understanding of this study and its goals. By learning more about this study, you'll be able to make an informed decision with your doctor.
You will receive the investigational study drug crizanlizumab (SEG101).
Crizanlizumab (SEG101) is being studied in adult sickle cell disease patients with vaso-occlusive crises.
Crizanlizumab (SEG101) is a type of drug called a monoclonal antibody. It binds to specific molecules, called P-selectin, that have been linked to sickle cell vaso-occlusive crises.
Crizanlizumab (SEG101) is given as an intravenous (IV) infusion directly into a vein and is administered by a health care provider.
Up to 55 patients will participate in this study.
Your treatment with the study drug will continue as long as it helps you, until you experience side effects that you can’t handle, until you decide not to participate in the study anymore, until the study reaches its end points, or until Novartis stops the study. Your study doctor can also decide to withdraw you from the study if he/she feels that this is best for you.